Back to Search
MORTON RUBENSTEIN, MD
MD
Internal Medicine Physician
NPI: 1326072224Individual
Specialties, Licenses & Credentials
Internal Medicine PhysicianPrimary
Internal Medicine
Code: 207R00000X
MD13822E(PA)
Critical Care Medicine (Internal Medicine) Physician
Internal Medicine — Critical Care Medicine
Code: 207RC0200X
MD13822E(PA)
Research & Publications (20)
Regenerative patterning in Swarm Robots: mutual benefits of research in robotics and stem cell biology.
PMID 19557691·Int J Dev Biol·2009
7-preclinical
Persistent cutaneous manifestations of hyperoxaluria after combined hepatorenal transplantation.
PMID 15347492·Dermatol Online J·2004
5-case
Short-term intravenous eptifibatide infusion combined with reduced dose recombinant tissue plasminogen activator inhibits platelet recruitment at sites of coronary artery injury.
PMID 14736451·J Am Coll Cardiol·2004
7-preclinical
Backbone modification alters the efficacy of antisense oligonucleotides directed against mRNA encoding either TGF-alpha or EGFR in the treatment of prostate cancer cell lines.
PMID 12616956·Methods Find Exp Clin Pharmacol·2002
8-other
Effectiveness of and adverse events after percutaneous coronary intervention in patients with mild versus severe renal failure.
PMID 11274940·Am J Cardiol·2001
8-other
Biotinylation of antisense oligonucleotides does not alter lipofectin enhanced cellular uptake in prostate cancer cell lines.
PMID 11876021·Methods Find Exp Clin Pharmacol·2001
8-other
Are patients with renal failure good candidates for percutaneous coronary revascularization in the new device era?
PMID 11113047·Circulation·2000
3-trial
Treatment of prostate and breast tumors employing mono- and bi-specific antisense oligonucleotides targeting apoptosis inhibitory proteins clusterin and bcl-2.
PMID 19533419·Med Oncol·2010
8-other
Multigene targeting of signal transduction pathways for the treatment of breast and prostate tumors: comparison between combination therapies employing bispecific oligonucleotides with either Rapamycin or Paclitaxel.
PMID 18686047·Med Oncol·2009
4-observational
Do intra-tumor alkaline micro-regions represent additional therapeutically privileged sites?
PMID 18364249·Med Hypotheses·2008
7-preclinical
Treatment of MCF-7 breast cancer cells employing mono- and bispecific antisense oligonucleotides having binding specificity toward proteins associated with autocrine regulated growth and BCL-2.
PMID 17972023·Med Oncol·2008
8-other
Local and systemic interleukin-18 and interleukin-18-binding protein in children with inflammatory bowel disease.
PMID 17879274·Inflamm Bowel Dis·2008
8-other
To what extent are the "sets" of biologic properties expressed by hypoxic cancer cells and by cancer "stem" cells equivalent, intersecting, disjoint or complementary? Some implications for the design of cancer therapies.
PMID 16934948·Med Hypotheses·2007
7-preclinical
Combination chemotherapy employing bispecific antisense oligonucleotides having binding sites directed against an autocrine regulated growth pathway and bcl-2 for the treatment of prostate tumors.
PMID 17917084·Med Oncol·2007
8-other
Bispecific antisense oligonucleotides having binding sites directed against an autocrine regulated growth pathway and bcl-2 for the treatment of prostate tumors.
PMID 17848743·Med Oncol·2007
4-observational
Targeting of biotinylated oligonucleotides to prostate tumors with antibody-based delivery vehicles.
PMID 17541843·J Drug Target·2007
7-preclinical
Outcome of a national Israeli cohort of pediatric systemic lupus erythematosus.
PMID 17402372·Lupus·2007
8-other
Bispecific antisense oligonucleotides with multiple binding sites for the treatment of prostate tumors and their applicability to combination therapy.
PMID 17136230·Methods Find Exp Clin Pharmacol·2006
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 97 BROADWELL LN
MECHANICSBURG, PA 17055 - Phone
- (717) 624-5260
Quick Facts
- NPI
- 1326072224
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 2
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile